Archive for June, 2009

Five Simple Words….

Posted by Kelli on June 28th, 2009


Five Simple Words to Keep Chronic Illness at Bay
by Madeleine Parish

When I was diagnosed with Chronic Fatigue Syndrome seven years ago, my illness began to consume my thoughts and time. Questions taunted me like unrelenting harpies: What will I do? How will I manage? Who will take care of me? To try to keep fears and symptoms at bay, I studied up on my diagnosis, and chronic illness in general, became fluent in the language of disability, medical research, and insurance claims. I even started to find that, if I met someone new, my illness became my calling card. Not five minutes into a conversation with a perfect stranger, I would hear myself quoting study results, describing in clinical terms, suspicions about retro-viruses and other prospective pathogens. I talked about my illness all the time! Gradually, I noticed the glazed look in the eyes of friends and strangers as I reviewed the latest research findings, or described in minute detail the effects of my recent treatments. My illness had become my identity! Over time, I realized I would manage just fine, even within the framework of chronic illness, provided I took responsibility for my mental, physical and spiritual well-being, and made health and healing my first priorities. In doing so, I learned to change my attitudes, behavior, lifestyle, even my vocabulary. These five words helped me do just that:

Please

Before chronic illness withered my penchant for independence, I took pride and refuge in self-reliance. Independence protected me–or so I thought–keeping me safe and invulnerable to rejection. Then, when I couldn’t get out of bed for days, or when pain wouldn’t allow me to negotiate stairs, I needed help. With my back against the proverbial wall, I saw self-sufficiency for the prideful defense it was, and that it no longer served me. So I dug inside for some courage, dusted off untested humility, and asked for help (PLEASE!) And when I did, I learned four things: First, some people are not only willing to help, they like helping and feel honored to be asked. Second, some people say no for reasons that have nothing to do with me. Third, whether people say yes or no, asking them doesn’t kill me. (I admit to some emotional bruising when I felt rejected, but, hey, I survived.) And fourth, by asking without shame or embarrassment, I learn to help others when they need or ask. Eventually I found that the family and friends who wouldn’t or couldn’t help no longer bothered me, and I appreciated more deeply those who did. As a result of their responses, I began to get a different vision of myself, vulnerable, but still loved, respected and valued.

Thank You

On, how I loved it at first! The way people scrunched their faces in sympathy when I said I had a chronic illness! I had what I wanted most: their attention. It didn’t take me long to learn that, while I had their attention, I didn’t have their interest. Unless, of course, they were chronic rescuers, people given to latching onto someone’s misfortune as their mission, their justification, their hook into unhealthy co-dependency. Self-pity is a turnoff to healthy people, and it keeps ill people so focused on themselves and fence in by illness, that they fail to see that, outside the fence, life goes on. What is the best, most effective antidote to self-pity? Gratitude! Thinking myself grateful doesn’t seem to work when I’m most shaky and self-pity is knocking for permission to enter. I have more success using gratitude as a wellness tool if I take action by writing a list of all the things I’m grateful for. The act of writing, plus the tangible, undeniable list seems to work better and faster than a mental checklist. The list doesn’t have to be long or complex. It can be as simple as the fact that I can feel the sun’s warmth on my face, or smell the honeysuckle’s perfume drifting over my neighbor’s fence. (That’s not to say the big things, like family, friends, food and shelter don’t count!) If I’ve cultivated an “attitude of gratitude” on days when I feel good physically, when I’ve accomplished something I’ve worked toward, and when I’m surrounded by loving family and friends, I find it easier to come up with a list when my symptoms are raging.

No

One of the difficult lessons I’ve learned through chronic illness is how to set limits on how much I allow other people, even those with good intentions, to interfere with my health. When I first got sick, I wanted people to like me even more than when I was well, because I was afraid my health challenge would ruin my relationships. That I’d be left alone and miserable for the rest of my life. Trying to prevent that possibility, I accepted invitations and kept commitments even when I was concerned they would affect my well-being. To avoid disappointing a hostess, for example, I said yes to a party, even thought parties, in particular, zapped my energy and required two or three days recovery time. Eventually, I learned to be more selective, and that I had choices. One, I could say a gentle but firm, “No, I’m sorry, not this time.” Two, I could go and leave when I had to, and before I was exhausted. Three, I could attend just part of the party, or just stop by for dessert. It was important that I participate as much as possible, because I didn’t want to lose touch with my social network. Over time, a few “friends” couldn’t accept my limitations and stopped inviting me. Those who understood my necessary boundaries, though, stuck with me, and our relationships are that much stronger as a result.

Yes

Back in the ’80s I had a boss who talked a lot about “creativity within constraints.” When she did, I nodded doing my best to look wise, or at least intellectually agile enough to know what she was talking about. But I didn’t. Sure, I knew what the words meant, but I couldn’t apply the concept to myself. Creativity? That was easy back then. After all, I was young, healthy, enthusiastic, ambitious. But constraints? What were they? A few years later, illness taught me a lot about constraints and the importance of saying YES to the opportunities I found within limitation. My first months of chronic illness were spent in such pain that I hadn’t time, energy or mind enough to consider creativity. Survival was my mode. Pure survival. But gradually my health began to improve. At first an occasional hour or two of feeling better, then back into the pit. Then the better times grew more frequent. Then one day I surprised myself by saying out loud, to an empty room, “I want to DO something. What can I DO?” One day I was bemoaning my conundrum to a friend. He listened patiently, nodded in all the right places, and when I finished he looked at me as if I really wanted to hear what he had to say. Sensing a moment of truth on its way, I sipped from my cup of tea and braced myself. “For years,” he said, “you’ve told me how you’ve wanted to write. And all I heard was how you didn’t have time. NOW YOU HAVE TIME!” Yes, I thought, HE’S RIGHT. But after I thought about it, I shook my head. I couldn’t imagine sitting at a desk and typing for hours on end. But I could envision working on a laptop that could travel from table to sofa to bed, writing a paragraph or a page as my muse and body allowed. When my friend left, I picked up the phone, called a local office supply store, and ordered a laptop. Two days later it arrived. I signed for it, took it from the delivery man, and carried it inside, holding it like a sacred vessel that held my future. It was! Some days I couldn’t think. Some days I could think, but not write. But some days I could tap out a few sentences then paragraphs. Then I wrote an essay. And another. A piece of fiction. And another. Chronic illness may have imposed new constraints, but I always have the power to learn to live creatively within them.

Enough

Desire, the Buddhas professed, is the route of all suffering. NO WAY! Desire got me promotions, new cars, nicer clothes, a better tennis serve. It’s what keeps me striving, aiming higher, trying harder, running faster… Desire also kept me thinking that what I had wasn’t good enough, that I wasn’t good enough and that the only answer to “not good enough” was MORE. After I became ill it became apparent to me that, if I wanted to live at all peacefully, I needed to learn the difference between wants and needs. Because if I lived in a state of unmet wants, I would be not only chronically ill, but chronically miserable, too. The reality is that, even if I am in physical pain, or I don’t otherwise feel or look as I would like, and even if my bank account is dwindling, or my wardrobe isn’t up to snuff, if I stay connected to my spiritual source and to loving family and friends, my basic needs ARE met. I don’t want to be sick. But I don’t need to be physically well to be happy. When I hear the MORE MONSTER rearing his head, when I feel his self-effacing steam trying to wilt my confidence, it’s important for me to say one word, clearly, firmly, confidently: ENOUGH!

© 2009 Madeleine Parish

Madeleine Parish is the author of “A Pilgrim’s Way–Meditations for Healing”. She lives and writes in Fairfield County, Connecticut.
Source: www.healingwell.com


This is something I really need to think about…

Good Day

Posted by Kelli on June 20th, 2009

Today was a good day, physically speaking. Today was the Lacrosse Day of Champions for my step son’s Lacrosse League. Rob coaches 2 teams & is the House League Director.

My day started very early, so last night I was in bed before 9:30 – unheard of when I’m not crashed out. This morning I rolled out of bed at 6:10am – amazing accomplishment considering I don’t normally get up til noon. Got dressed & packed up & out the door to get the van we were renting for the day. Finished at the Rental agency by 7.30. Head up north to the arena ( I live 20km/12mi from the arena) to drop off the other half. Off to pick up my stepson & grab breakfast & back to the arena by 9.30am. Help unpack the van.

I take a few minutes to watch the Peanuts play (those are the little anklebiters) & then off to be girl friday (even tho it’s Saturday).. Most of the next few hours was spent between doing some in-house tasks & sitting down to read. Oddly enuf, I was *still* doing good.. No pain, no fatigue.. So, at 11.30 I drop off my step-son & get my lunch. I come back by 12 & eat while Rob’s on the floor coaching the Novice kids.. He’s just bouncing off the walls in enthusiasm.. I had to run (yes, run-or as close as I can get to a run) to the change rooms to get an Ice pack for an injury – twice (yes, twice) When his game finishes, I head out to pick up his lunch while the third novice game is on to see who wins. I’m back shortly after 1pm & decide to head to his parent’s place for a nap.

So I’ve been a busy body with bits of activity & bits of no activity, but no real “rest” periods, not like my doc wants (I’ll explain rest to ya’ll another time).. But I’m still not having pain.. & not the devastating fatigue of the CFS.. What I haven’t done by this point is taken my meds… at 12 noon, I am supposed to take my codeine contin – 12 hour release that I take at 12 noon & 12 midnight.. So, no wonder when I wake up form my nap & I’m sore and achey and still & starting to hurt.. *this* is when I realize I haven’t taken my meds. Of course, where are they – the arena.

When I get to the arena Rob’s ready to go.. immediately loads up the van & off we go – no real time for me to take anything.. with a detour to Dollaramma & I fergot about my meds again.. So I don’t get my meds until dinner – we hit the Keg on the way home and while waiting in the bar for our table, I take them.. 5 of ‘em.. ya, that’s a small chunk of medication. But interestingly enough, I’ve started to feel better after I had gotten moving around.. And interestingly, My leggs didn’t ache when I got up from sitting at dinner like they normally do.. When I sit for extended periods, like a social chatty dinner that lasts almost 2 hours, then ya, the leggs are usually difficult to get moving..

So, now we’re home, the van’s unpacked, I’ve got the overnight info for parking the van cuz we’re not going to take it back tomorrow morning. I’ve gone on FaceBook & Feed my virtual roses.. I’ve done a blog post & now writing this one at almost 11pm and I am still going.. Where’s Rob? Crashed out on the bed. But I am heading to bed soon too..

But it’s been a good day… Am I gonna feel it tomorrow? Unfortunately, yes.

It’s not real.. Not for me apparently. :(

Posted by Kelli on June 20th, 2009

What would you do? How would you react? If you got told by the person that has been your primary support person for the last 3 + years.. That he/she doesn’t believe you’re sick? Doesn’t believe you’re really *that* tired? Doesn’t believe you’re in *that* much pain? And thinks it’s all in your head.

I was told the other day by the person who I look to most for help & support with my fms & everything else, exactly that. He doesn’t believe me. He thinks I’m either making it up & have fooled all the doctors and specialists, Or it’s all in my head. He said he’s never really believed me since he met me.. He thinks I’ve been lying to the world this whole time, that I have been putting myself through test after test after test, several invasive just to play sick? He thinks I’m a leach on the government rolls because I get disability (and we all know how easy that is to get). That it’s my self esteem that’s screwing me up. He’s thinks that I’ve got nothing of value.. Nothing to offer.. I’m nothing of value.. *sigh*

How much more of a stab in the heart is that?? How much more hurtful can one person be??

I’ve considered the option of leaving before, but not all that serious.. But now,. yes I am giving it serious thought. How can I stay here with this person who I should be looking to for help, but who does not really believe what I am going through is real. I have thought on & off that sometimes he doesn’t get it – but that makes me wonder if he even understand, let alone cares about me at all. It’s heart wrenching.

Sodium Oxybate Improves FMS Core Symptoms??

Posted by Kelli on June 15th, 2009

Data Suggests Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia

06/15/2009

PALO ALTO, Calif., June 15, 2009 — Jazz Pharmaceuticals’ (Nasdaq: JAZZ) sodium oxybate (JZP-6) demonstrated statistically significant and clinically meaningful improvement in pain and the core symptoms associated with fibromyalgia, according to Phase III data presented last week at the 2009 Associated Professional Sleep Societies meeting in Seattle, WA. These data have not been evaluated by the FDA or other regulatory authorities for use of sodium oxybate in the treatment of fibromyalgia.

Widespread chronic pain is the hallmark of fibromyalgia, but the vast majority of patients are also affected by a broader constellation of symptoms, including fatigue, sleep disturbances, cognitive dysfunction, and impaired physical function.

“The data showed that sodium oxybate improves the key symptoms of fibromyalgia: pain, fatigue, and sleep disturbances,” said Dr. Todd Swick, one of the study’s investigators and Medical Director of the Houston Sleep Center and Assistant Clinical Professor of Neurology at the University of Texas-Houston School of Medicine. “Millions of people are diagnosed with fibromyalgia and there is a continuing unmet need for therapies that address the constellation of symptoms that can have a significant impact on patients’ quality of life.”

The 14-week randomized, double-blind, placebo-controlled study included 548 adult patients with fibromyalgia randomized to one of three treatment arms: sodium oxybate 4.5 g/night, sodium oxybate 6 g/night or placebo. The primary outcome measure was the proportion of patients who achieved at least 30% reduction in pain from baseline to endpoint based on the Pain Visual Analog Scale (VAS).

At three months, 54.2% (p<0.001) of patients treated with sodium oxybate 4.5 g/night and 58.5% (p<0.001) of patients treated with sodium oxybate 6 g/night showed significantly greater reduction in pain as measured by at least a 30% improvement in baseline pain VAS score, compared with 35.2% of patients taking placebo using Last Observation Carried Forward analysis.

Additional Data Highlights

– Patients treated with sodium oxybate 4.5 g/night and 6g/night showed significant reductions in fatigue as early as Week 1 after dosing compared with placebo as measured by the Fatigue VAS (p<0.001). These differences were maintained throughout the 14 weeks of the study (p less than or equal to 0.009).

-- Patients taking sodium oxybate 4.5 g/night and 6g/night showed significant improvement in sleep patterns compared to placebo as measured by the Jenkins Sleep Scale (p<0.001).

-- Statistically significant improvements in mean scores on the Fibromyalgia Impact Questionnaire, a measure of daily function, and on Patient Global Impression of Change were seen in patients receiving sodium oxybate compared to placebo.

-- Sodium oxybate was generally well tolerated, with the majority of adverse events reported being mild to moderate in nature. Adverse events were similar to those seen in previous sodium oxybate experience.

-- In this study, the most common adverse events, with incidence greater than or equal to 5% and at least twice the rate of placebo, were headache, nausea, dizziness, vomiting, diarrhea, anxiety, and sinusitis.

Additional details on the data presented at the 2009 APSS can be found at http://www.journalsleep.org/PDF/AbstractBook2009.pdf (abstract 0984, p.354).

Development Plans

Jazz Pharmaceuticals has completed its second Phase III clinical trial of JZP-6 and expects to announce top-line results from this study around mid-2009. Assuming positive results for the second study, the company anticipates submitting a New Drug Application for sodium oxybate for the treatment of fibromyalgia to the U.S. Food and Drug Administration by the end of 2009. UCB anticipates filing in the EU shortly after. UCB has the exclusive marketing and distribution rights to sodium oxybate for fibromyalgia in Europe and some other countries outside North America and will manage registrations accordingly.

About Sodium Oxybate

Sodium oxybate is the sodium salt form of gamma-hydroxybutyrate, an endogenous neurotransmitter and metabolite of GABA. While the precise mechanism of action is unknown, the effects may be mediated in part through interaction with GABA(B) and GHB receptors. Sodium oxybate is the active ingredient in XYREM(R), approved by the FDA for the treatment of excessive daytime sleepiness (EDS) and cataplexy (the sudden loss of muscle tone) in adult patients with narcolepsy. The American Academy of Sleep Medicine recommends sodium oxybate as a standard of care for the U.S. Food and Drug Administration-approved indications. It is also approved by the European Medical Evaluation Agency (EMEA) for the treatment of narcolepsy with cataplexy in adult patients. Most commonly reported adverse drug reactions in narcolepsy patients are dizziness, nausea and headaches. Sodium oxybate has the potential to induce respiratory depression and neuropsychiatric events. Sodium oxybate has not been evaluated by regulators for the treatment of fibromyalgia and is not approved for this use. Additional safety information for Xyrem, including black box warnings, can be found in the full prescribing information at http://www.xyrem.com/prescribing-information.php.

About Fibromyalgia

Fibromyalgia, a chronic condition characterized by widespread pain, affects 0.5% – 5% of adults worldwide. Fibromyalgia is believed to be a central nervous system condition, resulting from neurological changes in how the brain perceives and responds to pain. In addition to pain, the main symptoms are fatigue, disturbed sleep and morning stiffness. The exact causes of fibromyalgia are unknown. It may be triggered by physical trauma, emotional stress, chronic pain or infection. Genetics, neurochemicals that affect pain modulation, neurohormones and sleep physiology abnormalities are thought to play a role. Research also has suggested a relationship between sleep and pain. Fibromyalgia patients experience a high prevalence of sleep problems, including a reduction in non-restorative or deep sleep.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information see http://www.JazzPharmaceuticals.com.

Jazz Pharmaceuticals “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements related to the development of Jazz Pharmaceuticals’ sodium oxybate (JZP-6) product candidate for the treatment of fibromyalgia, including the timing of results from the second Phase III pivotal clinical trial and the submission of a New Drug Application to the FDA. These forward-looking statements are based on the company’s current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals’ actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the outcomes of the company’s second Phase III clinical study of sodium oxybate for the treatment of fibromyalgia and the timing of the announcement of clinical results, and risks that a New Drug Application may not be submitted, or may be delayed, and that sodium oxybate for the treatment of fibromyalgia may not be approved for marketing by regulatory authorities. These and other risk factors are discussed under “Risk Factors” in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on May 7, 2009. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

(C) 2009 Jazz Pharmaceuticals, Inc.
SOURCE Jazz Pharmaceuticals, Inc.
Web Site: http://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia

06/09/2009

PALO ALTO, Calif., June 9 — Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that data from the company’s first Phase III clinical trial of sodium oxybate (JZP-6) for the treatment of fibromyalgia will be presented this week during the Associated Professional Sleep Societies (APSS) 2009 Annual Meeting in Seattle, Washington and also during the European League Against Rheumatism (EULAR) Congress in Copenhagen, Denmark.

Following are the details on each of these data presentations.

– At APSS on June 10, 2009, Dr. Todd Swick will be presenting a poster entitled “Impaired Sleep and Daytime Functioning at Baseline in Subjects with Fibromyalgia: a 14-week Randomized, Double-blind, Placebo-controlled Trial of Sodium Oxybate” in the 10:15 am-12:15 pm poster session.

– At APSS on June 11, 2009 at 9:00 am in Ballroom 6E, Dr. Swick will also deliver an oral presentation entitled “Sodium Oxybate Improves Pain, Fatigue, and Sleep in Fibromyalgia: Results from a 14-week Randomized, Double-blind, Placebo-controlled Study.”

– At EULAR on June 12, 2009, in Room C2 from 5:30-7:00 pm, Dr. I. Jon Russell will be presenting “Sodium Oxybate in the Treatment of Fibromyalgia” at a UCB-sponsored Symposium entitled: “Fibromyalgia: How Much More than Pain?” The symposium will be chaired by Dr. Ernest Choy and also features Dr. Gilles Lavigne and Dr. Michael Spaeth as speakers.

Jazz Pharmaceuticals has completed a second Phase III pivotal clinical trial of JZP-6 and expects to announce top-line results from that study in mid-2009. Assuming positive results in the second study, the company anticipates submitting a New Drug Application for sodium oxybate for the treatment of fibromyalgia to the U.S. Food and Drug Administration by the end of 2009.

About Sodium Oxybate

Sodium oxybate is the sodium salt form of gamma-hydroxybutyrate, an endogenous neurotransmitter and metabolite of GABA. While the precise mechanism of action is unknown, the effects may be mediated in part through interaction with GABA(B) and GHB receptors. Sodium oxybate is the active ingredient in XYREM(R), approved by the FDA for the treatment of excessive daytime sleepiness and cataplexy (the sudden loss of muscle tone) in adult patients with narcolepsy. The American Academy of Sleep Medicine recommends sodium oxybate as a standard of care for the U.S. Food and Drug Administration-approved indications. It is also approved by the European Medical Evaluation Agency for the treatment of narcolepsy with cataplexy in adult patients. Most commonly reported adverse drug reactions in narcolepsy patients are dizziness, nausea and headaches. Sodium oxybate has the potential to induce respiratory depression and neuropsychiatric events. Sodium oxybate has not been evaluated by regulators for the treatment of fibromyalgia and is not approved for this use.

About Fibromyalgia

Fibromyalgia, a chronic condition characterized by widespread pain, affects 0.5% – 5% of adults worldwide. Fibromyalgia is believed to be a central nervous system condition, resulting from neurological changes in how the brain perceives and responds to pain. In addition to pain, the main symptoms are fatigue, disturbed sleep and morning stiffness. The exact causes of fibromyalgia are unknown. It may be triggered by physical trauma, emotional stress, chronic pain or infection. Genetics, neurochemicals that affect pain modulation, neurohormones and sleep physiology abnormalities are thought to play a role. Research also has suggested a relationship between sleep and pain. Fibromyalgia patients experience a high prevalence of sleep problems, including a reduction in non-restorative or deep sleep.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information please see http://www.JazzPharmaceuticals.com.

Jazz Pharmaceuticals “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements related to the development of Jazz Pharmaceuticals’ sodium oxybate (JZP-6) product candidate for the treatment of fibromyalgia, including the timing of results from the second Phase III pivotal clinical trial and the submission of a New Drug Application to the FDA. These forward-looking statements are based on the company’s current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals’ actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the outcomes of the company’s second Phase III clinical study of sodium oxybate for the treatment of fibromyalgia and the timing of the announcement of clinical results, and risks that a New Drug Application may not be submitted, or may be delayed, and that sodium oxybate for the treatment of fibromyalgia may not be approved for marketing by regulatory authorities. These and other risk factors are discussed under “Risk Factors” in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on May 7, 2009. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

(C) 2009 Jazz Pharmaceuticals, Inc.
SOURCE Jazz Pharmaceuticals, Inc.
CONTACT: Willie Quinn, Executive Director, Corporate Development of Jazz Pharmaceuticals, Inc.,
+1-650-496-2800, investorinfo@jazzpharmaceuticals.com
Web Site: http://www.jazzpharmaceuticals.com


Montreal Pain Researcher Joins Canadian Medical Hall of Fame

By Martin C. Barry
June 2009

Dr. Ronald Melzack’s interest in studying pain started off as a scientific problem, much like studying vision or hearing. “It was just plain curiosity about pain,” he said about his recent induction into the Canadian Medical Hall of Fame.

It wasn’t until he was a postdoctoral fellow in medical school at the University of Oregon and “met all kinds of people in terrible pain that could not be treated” that the study of chronic pain became his lifelong passion.

Last month during a ceremony in Montreal, Melzack was inducted into this country’s medical hall of fame along with four other individuals recognized for winning their place in Canadian medical history. Located in London, Ont., the hall of fame is dedicated to honouring Canadians who have changed the world’s health care landscape.

“I’m thrilled,” Melzack said of becoming a member of the Hall of Fame that has honoured such medical pioneers as Banting and Best, known for their discovery of insulin. Melzack’s pioneering research into pain mechanisms and pain control spans more than a half century and has had a major impact on every field of medicine dealing with patients who suffer from pain, in particular chronic pain.

Ronald Melzack is “thrilled” with his induction into the medical hall of fame Photo: Martin C. Barry

Born in Montreal, Melzack first became interested in the connection between pain and environment at McGill when he studied the reactions of dogs to pain stimulus. For the first six months of their lives, one group of dogs was raised in kennels while the others were raised in homes with small children. The dogs who had no interaction with children reacted more to “being pinched.”

A leader and visionary in his field, Melzack made four major contributions in the field of pain.

With the support of Dr. Joseph Stratford, Melzack co-founded the first pain clinic in Canada known as the McGill University Montreal General Hospital Pain Center where he served as research director from 1974 to 2000. The clinic is known to be one of the best organized centres for pain treatment in the world.

In 1965, Melzack developed the gate-control theory of pain in collaboration with neurophysiologist Dr. Patrick Wall.

The theory produced an explosive growth in research and resulted in experimental and clinical psychology becoming an integral part of pain research and therapy. Then in 1968, Melzack published an extension of the gate theory, proposing that pain is a subjective, multidimensional experience produced by parallel neural networks.

Another breakthrough was the development in the mid-70s of the McGill Pain Questionnaire, now the most widely used method worldwide for measuring pain in clinical research. It was developed during Melzack’s postdoctoral years, when he recorded more than 100 words to describe pain. Then with the help of a statistician, he obtained quantitative measures for each descriptor.

His fascination with phantom limb pain led to the publication in 1989 of the “neuromatrix theor y of pain.” In it he proposes that we are born with a genetically determined neural network that generates the perception of the body, the sense of self, and can also generate chronic pain, even when no limbs are present.

The world’s knowledge of pain might be a different today if Melzack had chosen to pursue a different path. While working toward his postgraduate and doctoral degrees during the early 1950s, his brother, Louis, was establishing the foundations of the Classic Book Shops chain that would eventually become one of Canada’s leading retailers of paperbacks.

“They wanted me to go into the book business and I didn’t want to,” he said. “By this time I was really hooked on psychology. Louis thought an academic life was nice, but I would never really earn a living.”

That’s when Dr. Victor Goldbloom, who was then a young pediatrician and a regular customer at one of the book shops, advised the family that they should give the future Dr. Melzack their full support. Goldbloom remains in touch with him to this day.

Mrs. Hull, whom Melzack had met in the course of his postdoctoral research, was instrumental in developing the McGill Pain Questionnaire. A diabetic, she experienced phantom pain following the amputation of her legs. “She would get throbbing pain, burning pain, crushing, all these adjectives,” Melzack said. “And then I began to write down all these adjectives. And then other patients would use other adjectives – a variety of them.”

Pain researchers are getting a better understanding of a condition known as fibromyalgia, according to Melzack. “The stress system is highly involved in it,” he said. “We know that there are trigger points, sensitive areas in the body where you’re likely to find the same pattern in virtually everybody, which means that these muscles seem to be under some strange tension for reasons not known. It produces depression and is activated by depression. But now there’s so much more research on it and it’s become so prevalent.”

Source: http://theseniortimes.com

Under Construction

Posted by Kelli on June 15th, 2009

As you can see, my blog has changed a bit.. More changes are coming.. All the green will be switched to shade of purple, I hope. My other half says I can’t, but I am tech-savvy enough to be able to make the changes in the wp code & image files :) Just not 100% sure I can do justice to the background images.. We’ll see.. If I can’t manage it, I have a second choice, which would be easier to dump into purple – I just like this look better :)

Some widgets will be added down the side.. I still need to update my links, and I apologize for that.. I didn’t get much notice that I was changing my look.

I will still be adding posts when I can.. & as you can see by the NIN post below, they are not always health related *g*.. Enjoy!

Trent Reznor takes Twitter Vow of Silence

Posted by Kelli on June 15th, 2009


Trent Reznor takes Twitter Vow of Silence

Nine Inch Nails man blames ‘Metal Sludge’ for ruining social networking

Jun 12, 2009

Nine Inch NailsTrent Reznor has taken a vow of silence on Twitter.

The singer had been using the mirco blog site to banter with fans, give his opinions and infamously declare that Chris Cornell’s last album was so bad it made him feel “uncomfortable”.

However Reznor has now decided he will not be using his account anymore, except to make announcements, and he will not be replying to anyone.

According to Musically.com, the singer blamed spammers and haters for his self-imposed silence.

“I will be tuning out of the social networking sites because at the end of the day it’s now doing more harm than good in the bigger picture and the experiment seems to have yielded a result. Idiots rule,” he wrote.

He also blamed hardcore fans who were targeting him, adding: “Looks like the Metal Sludge contingency has discovered Twitter! Finally! For those of you that don’t know what this is, please let me explain. Metal Sludge is the home of the absolutely worst people I’ve ever come across. It’s populated mainly by unattractive plump females who publicly fantasize about having sex with guys in bands. Kind of like a role-playing game where people nobody will f**k make up stories about their incredible sexual encounters with people they wish they could f**k.

“It would be kind of funny in a sad and pathetic way except the fun doesn’t stop there – hate and good old-fashioned outright blatant racism are also encouraged to spice things up and remind you how truly ugly these scourges are. Truly ugly on the inside (the outside is obvious).”

Source: http://www.nme.com

Facebook

Posted by Kelli on June 13th, 2009

Those of you who got the request, please confirm this is my Blog..  :) I’m me..  :) With the lovely May 12th, 2009 purple ribbon..

Thanks!

Kel!

Blog Transition

Posted by Kelli on June 12th, 2009

My SO has decided that he wants us to go from hosted wordpress to unhosted wordpress..  So, if there are some glitches this afternoon and evening, that’s why and you have my apologies..  There will also be a new look I’m sure, so keep an eye out! :)